A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node-positive early stage breast cancer.

Study Of Letrozole Extension (SOLE)

Study Chairs
Dr. Marco Colleoni - Milano, Italy

Statisticians
Dr. Meredith Regan

Lead Trial Coordinator
Holly Shaw

Data Managers
Monica Greco, Adriana Karausch

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
November 8, 2007

Final Accrual
4884 patients

Targeted Accrual
4800 patients

Date of closure
October 8, 2012

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login